New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
08:03 EDTHALOHalozyme announces that rrial of Hylenex recombinant met primary endpoint
Halozyme announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex recombinant and a new formulation of Hylenex currently under FDA review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion in comparison to no pre-treatment. In accordance with the trial protocol pre-specified analysis of the endpoints, data from the two patient groups treated with Hylenex formulations were pooled in comparison to a group consisting of patients using standard CSII with rapid acting analog insulin alone. Adverse events were similar across the treatment and control groups. The most common treatment related adverse event in the Hylenex groups was mild infusion site discomfort.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2015
08:31 EDTHALOHalozyme names Michael LaBarre chief scientific officer
Halozyme named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. "Mike has deep experience characterizing early stage assets, making him an ideal leader for our research organization as we invest further in our promising pipeline," said Dr. Helen Torley, president and chief executive officer. "We have a full agenda for the second half of 2015 as we broaden the study of our investigational new drug PEGPH20 in multiple tumor types and prepare for our pivotal phase 3 study in pancreatic cancer patients. I am pleased to have a proven leader of Mike's caliber to guide our research efforts as we invest for future growth."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use